ArticlePloS one2016
Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 6 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.Annals of laboratory medicine · 2024Guideline
- Diagnostic performance of GcfDNA in kidney allograft rejection: a meta-analysis.Frontiers in physiology · 2023Pooled it
- Clinical Practice Guidelines for Pre-Analytical Procedures of Plasma Epidermal Growth Factor Receptor Variant Testing.Annals of laboratory medicine · 2022Guideline
- Guidelines for pre-analytical conditions for assessing the methylation of circulating cell-free DNA.Clinical epigenetics · 2021Pooled it
- Specialized Blood Collection Tubes for Liquid Biopsy: Improving the Pre-analytical Conditions.Molecular diagnosis & therapy · 2020Pooled it
- Update on the types and usage of liquid biopsies in the clinical setting: a systematic review.BMC cancer · 2018Pooled it
- Quantifying circulating cell-free DNA in humans.Scientific reports · 2019Trial
- Impact of methodological variability on the prognostic performance of circulating tumor DNA in colorectal cancer: A systematic review and meta-analysis.The journal of liquid biopsy · 2026Review
- Adaptive epithelial-mesenchymal bi-directional transition: A key invasive plasticity for tumor metastasis.iScience · 2026Review
- Donor-Derived Cell-Free DNA Levels Predict Renal Allograft Biopsy Findings in a UK Single-Centre Study. Results of the KORAD Study.International journal of immunogenetics · 2026Article
- Pre-analytical optimization of cell-free DNA and extracellular vesicle-derived DNA for mutation detection in liquid biopsies.Molecular oncology · 2026Article
- Feasibility of serial cfDNA measurement after perflubutane microbubble (SonazoidBMC research notes · 2026Article
- Expert recommendations for PIK3CA testing in HR+/HER2- locally advanced and metastatic breast cancer.NPJ breast cancer · 2026Review
- Liquid biopsy in malignant primary bone tumors: Clinical applications of circulating tumor DNA and circulating tumor cells for diagnosis, prognosis and treatment monitoring (Review).Oncology reports · 2026Review
- Analytical validation of a multiplexed peptide microarray for multi-antigen Epstein-Barr virus serological profiling across diverse clinical specimens.Frontiers in immunology · 2026Article
- Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction.Frontiers in cell and developmental biology · 2026Review
- Cell type inference in cell-free nucleic acid liquid biopsy.Nature biotechnology · 2025Review
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Review
- Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer.Nature communications · 2025Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMaking liquid biopsy testing widely available requires a concept to ship whole blood at ambient temperatures while retaining the integrity of the cell-free DNA (cfDNA) population and stability of blood cells to prevent dilution of circulating tumor DNA (ctDNA) with wild-type genomic DNA. The cell- and DNA-stabilizing properties of Streck Cell-Free DNA BCT blood collection tubes (cfDNA BCTs) were evaluated to determine if they can be utilized in combination with highly sensitive mutation detection technologies.
methodsVenous blood from healthy donors or patients with advanced colorectal cancer (CRC) was collected in cfDNA BCTs and standard K2EDTA tubes. Tubes were stored at different temperatures for various times before plasma preparation and DNA extraction. The isolated cfDNA was analyzed for overall DNA yield of short and long DNA fragments using qPCR as well as for mutational changes using BEAMing and Plasma Safe-Sequencing (Safe-SeqS).
resultsCollection of whole blood from healthy individuals in cfDNA BCTs and storage for up to 5 days at room temperature did not affect the DNA yield and mutation background levels (n = 60). Low-frequency mutant DNA spiked into normal blood samples as well as mutant circulating tumor DNA in blood samples from CRC patients collected in cfDNA BCTs were reliably detected after 3 days of storage at room temperature. However, blood samples stored at ≤ 10°C and at 40°C for an extended period of time showed elevated normal genomic DNA levels and an abnormally large cellular plasma interface as well as lower plasma volumes.
conclusionWhole blood shipped in cfDNA BCTs over several days can be used for downstream liquid biopsy testing using BEAMing and Safe-SeqS. Since the shipping temperature is a critical factor, special care has to be taken to maintain a defined room temperature range to obtain reliable mutation testing results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.